| Budget Amount *help |
¥4,810,000 (Direct Cost: ¥3,700,000、Indirect Cost: ¥1,110,000)
Fiscal Year 2018: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2017: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
Fiscal Year 2016: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
|
|---|
| Outline of Final Research Achievements |
Primary aldosteronism (PAs) is more strongly associated with cardiovascular complications and organ damage. Furthermore, approximately 10% of patients diagnosed with essential hypertension also have PA. We and others recently reported a very high frequency of somatic mutations in the KCNJ5 gene in PAs, but the detailed mechanism has not been evaluated. Therefore, we created a KCNJ5 mutant mouse model, and started to evaluate the onset mechanism of primary aldosteronism. The mutant KCNJ5 mice have not been found to have adrenal hyperplasia or tumorigenesis, but over expression of aldosterone synthetase was confirmed. In the future, we will continue to study in more detail and aim for the application to diagnosis and treatment of primary aldosteronism.
|
